GlassScriptPhysician profile
Dan Sotirescu
NPI 1942209234
$114,044.61
in general payments reported to CMS, 2019-2025
52 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $19K · 2021: $20K · 2022: $10K · 2023: $15K · 2024: $8,133 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $4,335 · Food and Beverage: $1,727 · Honoraria: $1,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,260 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,834.50 |
| Travel and Lodging | $4,334.58 |
| Food and Beverage | $1,727.43 |
| Honoraria | $1,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,260.00 |
| Education | $106.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $11,747.97 | 2019-2021 | |
| Foundation Medicine, INC. | $11,009.94 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $9,503.41 | 2019-2024 | |
| Incyte Corporation | $7,458.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $7,072.77 | 2019-2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $6,657.99 | 2019 | |
| Seagen INC. | $6,123.05 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Pharmacosmos Therapeutics INC. | $6,097.21 | 2021-2023 | Monoferric |
| Exelixis INC. | $6,009.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,091.36 | 2019 | |
| Gilead Sciences, INC. | $4,278.72 | 2019-2021 | |
| Celgene Corporation | $3,289.33 | 2019-2023 | Reblozyl |
| Janssen Biotech, INC. | $2,946.28 | 2019-2023 | Imbruvica |
| US Oncology Corporate, INC. | $2,908.22 | 2022 | |
| Karyopharm Therapeutics INC. | $2,338.48 | 2020-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Sotirescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.